Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
| Autor: | Paolo Abada, Baek Yeol Ryoo, Takuji Okusaka, Jean-Marc Phelip, Etsuro Hatano, Chia Jui Yen, Shinichi Ohkawa, Ronnie T.P. Poon, Tulio Eduardo Flesch Pfiffer, Davide Pastorelli, Jean-Frédéric Blanc, Masatoshi Kudo, Hyun Cheol Chung, Andrew X. Zhu, Ian Chau, Chung Pin Li, Yanzhi Hsu, Joon Oh Park, Katerina Kopeckova, Giovanni Brandi |
|---|---|
| Přispěvatelé: | Chau, Ian, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frédéric, Kudo, Masatoshi, Pfiffer, Tulio, Hatano, Etsuro, Chung, Hyun Cheol, Kopeckova, Katerina, Phelip, Jean-Marc, Brandi, Giovanni, Ohkawa, Shinichi, Li, Chung-Pin, Okusaka, Takuji, Hsu, Yanzhi, Abada, Paolo B., Zhu, Andrew X. |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Kaplan-Meier Estimate Antibodies Monoclonal Humanized Placebo Gastroenterology Disease-Free Survival Article Ramucirumab law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Carcinoma Humans neoplasms Aged business.industry Liver Neoplasms digestive oral and skin physiology Antibodies Monoclonal Middle Aged medicine.disease digestive system diseases Radiography Clinical trial Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma embryonic structures Monoclonal Female 030211 gastroenterology & hepatology alpha-Fetoproteins Alpha-fetoprotein business |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Background Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. Methods Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. Results Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P P P P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P P Conclusions Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink